Related references
Note: Only part of the references are listed.Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation
J. P. Robinson et al.
ONCOGENE (2010)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
Tumour cell survival signalling by the ERK1/2 pathway
K. Balmanno et al.
CELL DEATH AND DIFFERENTIATION (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations
Cameron Brennan et al.
PLOS ONE (2009)
Temozolomide preferentially depletes cancer stem cells in glioblastoma
Dagmar Beier et al.
CANCER RESEARCH (2008)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Constitutive activation of Raf-1 induces glioma formation in mice
Yelena Lyustikman et al.
NEOPLASIA (2008)
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari et al.
GENES & DEVELOPMENT (2007)
Clinical experience of MEK inhibitors in cancer therapy
Ding Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Essential role for Ras signaling in glioblastoma maintenance
SL Holmen et al.
CANCER RESEARCH (2005)
mTOR promotes urvival and astrocytic characteristics induced by Pten/Akt signaling in glioblastoma
XY Hu et al.
NEOPLASIA (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
EC Holland et al.
NATURE GENETICS (2000)
Share Paper
